Heat Stable Rotavirus vaccine
To combat this killer of children, the International Medica Foundation has a rotavirus vaccine program and is currently developing a neonatal oral rotavirus vaccine, RotaShield®, which has the potential to protect infants earlier in life than the current rotavirus vaccines. The vaccine also is intended to be very affordable to families in low-income, less-developed countries.

Milestone in Phase II Clinical Trial for Rotavirus Vaccine reached
International Medica Foundation's Phase II clinical trial of its oral rotavirus vaccine, RotaShield®, has reached the milestone of nearly 1,000 infants in the study that have recieved their second of two doses of either RotaShield or a placebo.

Rotavirus Hunters
International Medica Foundation and Dr. Leonard Ruiz are featured in the January issue of Minnesota Business Magazine

International Medica Foundation Starts Phase II Clinical Trial for Rotavirus Vaccine
Lower-cost vaccine to prevent diarrhea to be tested in Africa

IDT Biologika GmbH produces RotaShield
All of the vaccine and placebo for the trial was manufactured in a state of the art vaccine manufacturing facility in Dessau-Rosslau, Germany.